Clinical Application of Paroxetine for Chronic Benzodiazepine Users at an Internal Medicine Clinic
|
Accession number;06A0417274
|
| Title;Clinical Application of Paroxetine for Chronic Benzodiazepine Users at an Internal Medicine Clinic |
| Author;
NAKAO MUTSUHIRO
(Teikyo Univ.)
NAKAO MUTSUHIRO
(Teikyo Univ., Fac. Medicine, JPN)
TAKEUCHI TAKEAKI
(Teikyo Univ.)
TAKEUCHI TAKEAKI
(Teikyo Univ., Fac. Medicine, JPN)
NOMURA KYOKO
(Teikyo Univ.)
NOMURA KYOKO
(Teikyo Univ., Fac. Medicine, JPN)
TERAMOTO TAMIO
(Teikyo Univ., Sch. of Med.)
YANO EIJI
(Teikyo Univ., Fac. Medicine, JPN)
|
Journal Title;Ther Res
|
Journal Code:Y0681A
|
ISSN:0289-8020
|
|
VOL.27;NO.5;PAGE.859-867(2006)
|
| Figure&Table&Reference;FIG.2, TBL.3, REF.29 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;Background: Chronic benzodiazepine (BZP) users often suffer from depression, or have difficulty of BZP withdrawal even when major depression is not apparent. Method: To examine treatment and taper-off effects by selective serotonin reuptake inhibitor (SSRI) in chronic BZP users, 97 outpatients attending an internal medicine clinic were recruited for the study. All had taken BZP for at least three months. The DSM-IV interviews were used to detect major depression with Hamilton Rating Scales for Depression (HAM-D) and Anxiety (HAM-A). Results: As results, 31(32%) were diagnosed with major depression; both HAM-D and HAM-A scores turned to be significantly lower in the 16 major depressive patients who randomly received additional 20-40mg/day of paroxetine for eight weeks, compared to the 15 patients keeping the same drug regimen. The remaining 66 without major depression were randomly assigned to an SSRI-assisted BZP-reduction group (10-20 mg/day of paroxetine, n=22), simple BZP-reduction group (n=23), or no BZP-reduction group (n=21). A standardized eight-week-program involving gradual BZP discontinuation was performed in the two BZP-reduction groups. Of these patients, 45% succeeded in BZP free after the completion of the program in the SSRI-assisted BZP-reduction group, whereas 17% succeeded in the simple BZP-reduction group. Taking SSRI significantly contributed to the success of BZP free, controlling for the effects of age, sex, period of taking BZP, and HAM-D and HAM -A scores at baseline. Conclusions: Major depression is prevalent in chronic BZP users among internal medicine outpatients, and SSRI may have beneficial effects both for the improvement of depressive symptoms and for the withdrawal of BZP. (author abst.) |
|
|
|
Related Articles;
|
|
